<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Endoscopic palliation of esophageal cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Endoscopic palliation of esophageal cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Endoscopic palliation of esophageal cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John R Saltzman, MD, FACP, FACG, FASGE, AGAF</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas G Adler, MD, FACG, AGAF, FASGE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H107180395"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Esophageal cancer is often diagnosed at an advanced and/or incurable stage. Although surgical palliation may be considered in patients without metastatic disease who are good operative risk, locally unresectable or medically poor-risk patients may achieve palliation of dysphagia from nonoperative methods. Palliation of dysphagia can often be achieved by radiation, with or without chemotherapy. (See  <a class="medical medical_review" href="/z/d/html/2472.html" rel="external">"Management of locally advanced, unresectable and inoperable esophageal cancer"</a>.)</p><p>However, improvement in swallowing may not occur for several weeks, and not all patients can tolerate these treatments. These individuals can be plagued by symptoms of esophageal obstruction, fistulae, dysphagia, odynophagia, aspiration, poor nutrition, and weight loss.</p><p>Symptomatic patients who are not candidates for chemoradiotherapy, or who have recurrent dysphagia following definitive chemoradiotherapy may benefit from palliative endoscopic maneuvers. While a variety of endoscopic methods have been described, esophageal stenting is probably most commonly used [<a href="#rid1">1</a>]. Guidelines from the American Society for Gastrointestinal Endoscopy recommended esophageal stenting as the preferred method for palliation of dysphagia and fistulas in patients with esophageal cancer [<a href="#rid2">2</a>]. The degree of palliation with any of these methods is typically incomplete, underscoring that more effective approaches are still needed. As a general rule, palliative approaches for inoperable esophageal cancer should be based upon patient and tumor characteristics, goals of care, and patient and clinician preferences [<a href="#rid2">2,3</a>].</p><p>This topic will provide an overview of the endoscopic options available for the palliation of esophageal cancer. The use of expandable stents in treating esophageal obstruction is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2677.html" rel="external">"Endoscopic stenting for palliation of malignant esophageal obstruction"</a>.)</p><p class="headingAnchor" id="H1399556919"><span class="h1">ENDOSCOPIC STENTING</span><span class="headingEndMark"> — </span>Patients with advanced stages of esophageal cancer or those who are poor surgical candidates can be offered stenting as a palliative treatment for dysphagia. Stenting can also be used for palliation of patients with postoperative tumor recurrence [<a href="#rid4">4</a>]. This topic is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2677.html" rel="external">"Endoscopic stenting for palliation of malignant esophageal obstruction"</a>.)</p><p class="headingAnchor" id="H107180403"><span class="h1">ESOPHAGEAL DILATION</span><span class="headingEndMark"> — </span>Esophageal dilatation with either through-the-scope balloon or wire-guided polyvinyl bougies can provide temporary relief of dysphagia until more definitive treatment can be accomplished. Most malignant strictures can be safely dilated to 16 or 17 mm in several sessions [<a href="#rid5">5</a>]. However, repeat dilatation is usually required every two to four weeks. Esophageal dilation is also associated with risk of perforation, especially if performed by blind Maloney dilation during radiotherapy [<a href="#rid6">6-9</a>]. In clinical practice, dilation of malignant esophageal strictures is uncommonly performed given the short-term benefit and associated risks. (See  <a class="medical medical_review" href="/z/d/html/2275.html" rel="external">"Complications of endoscopic esophageal stricture dilation"</a>.)</p><p class="headingAnchor" id="H107180451"><span class="h1">PHOTODYNAMIC THERAPY</span></p><p class="headingAnchor" id="H3683994214"><span class="h2">General principles</span><span class="headingEndMark"> — </span>Photodynamic therapy (PDT), a tissue ablative technique, uses a photosensitizing agent in combination with endoscopic low power laser exposure. Only one photosensitizing agent, <a class="drug drug_general" data-topicid="9791" href="/z/d/drug information/9791.html" rel="external">porfimer</a> sodium (Photofrin), is available in the United States. Porfimer sodium is a hematoporphyrin derivative, which is approved for the palliation of esophageal cancer. PDT with porfimer sodium is thought to have a direct toxic effect on malignant cells via the production of singlet oxygen, which damages the microvasculature of the tumor and renders it ischemic [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/4382.html" rel="external">"Endobronchial photodynamic therapy in the management of airway disease in adults", section on 'Principles of photodynamic therapy'</a>.)</p><p><a class="drug drug_general" data-topicid="9791" href="/z/d/drug information/9791.html" rel="external">Porfimer</a> sodium accumulates in malignant tissue after intravenous injection, and the area is then exposed to an endoscopically placed low power laser diffuser with monochrome light (630 nm), which initiates a photochemical reaction that results in tumor necrosis. The malignant tissue can be repeatedly treated in order to provide optimal tissue ablation.</p><p class="headingAnchor" id="H107180459"><span class="h2">Patients with advanced disease</span><span class="headingEndMark"> — </span>With the widespread availability of self-expandable metal stents (SEMS) for esophageal cancer, PDT is less commonly utilized as initial therapy for palliation of malignant dysphagia. For patients with SEMS, PDT can be used to treat stent occlusion related to tissue ingrowth or overgrowth. (See  <a class="medical medical_review" href="/z/d/html/2677.html" rel="external">"Endoscopic stenting for palliation of malignant esophageal obstruction", section on 'Stent occlusion'</a>.)</p><p>PDT has also been studied in combination with argon plasma coagulation (APC). (See <a class="local">'Argon plasma coagulation'</a> below.)</p><p>Studies suggest that PDT provides palliation from dysphagia for patients with advanced esophageal cancer and that PDT with a second-generation photosensitizer has shown promise for patients with local failure after chemoradiotherapy [<a href="#rid11">11-14</a>]. In a study including 121 patients with esophageal cancer and local failure following chemoradiotherapy, salvage PDT using talaporfin sodium was associated with higher rates of local complete response compared with PDT using <a class="drug drug_general" data-topicid="9791" href="/z/d/drug information/9791.html" rel="external">porfimer</a> sodium (69 versus 58 percent) [<a href="#rid13">13</a>]. Adverse events including skin phototoxicity, esophageal stricture, and esophageal fistula were less common in the talaporfin sodium group. (See <a class="local">'General principles'</a> above.)</p><p>In earlier studies, other adverse events reported with PDT were chest pain and worsening dysphagia [<a href="#rid10">10,15</a>]. Although <a class="drug drug_general" data-topicid="9791" href="/z/d/drug information/9791.html" rel="external">porfimer</a> sodium is cleared from a variety of tissues within 40 to 72 hours after injection, tumors, the skin, and some organs (ie, liver, spleen) retain the drug for a longer period. Skin photosensitivity may persist for four to six weeks after the treatment; sunscreens are ineffective since they do not block visible light. Agents with less phototoxicity (eg, talaporfin sodium) may be the future of PDT therapy [<a href="#rid12">12,13</a>].</p><p class="headingAnchor" id="H107180467"><span class="h2">Patients with early-stage disease who are not surgical candidates</span><span class="headingEndMark"> — </span>Another potential use of PDT is for patients with early-stage disease who pose a high surgical risk or those who refuse surgery [<a href="#rid16">16,17</a>]. In the largest series of 123 such patients who were recommended for nonoperative treatment, the complete response rate at six months was 87 percent with PDT alone or as a component of multimodality therapy, and the five-year disease-specific survival rate was 74 percent [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H107180475"><span class="h1">ARGON PLASMA COAGULATION</span><span class="headingEndMark"> — </span>Argon plasma coagulation (APC) is a technique of monopolar, noncontact, high frequency electrocautery that uses ionized, electrically charged argon gas to cause tissue coagulation and tumor destruction. APC has been used to palliate tumors in a variety of gastrointestinal lumens. In a study of pulsed versus forced APC that included 51 patients with esophageal or esophagogastric junction cancer, an overall response was seen in 85 percent and dysphagia improved in 94 percent of patients [<a href="#rid18">18</a>]. The most common adverse event was bleeding. (See  <a class="medical medical_review" href="/z/d/html/2576.html" rel="external">"Argon plasma coagulation in the management of gastrointestinal hemorrhage"</a>.)</p><p>Outcome data for APC compared with stent placement are limited [<a href="#rid19">19</a>]. In an observational study of 228 patients with inoperable esophageal cancer, APC was associated with longer median survival compared with placement of a self-expandable metal stent (257 versus 102 days), but this difference was likely due to patient selection.</p><p>APC has also been studied in combination with brachytherapy and photodynamic therapy (PDT). A randomized trial with 93 patients with malignant dysphagia assigned patients to treatment with APC plus brachytherapy, APC plus PDT, or APC alone [<a href="#rid20">20</a>]. Patients treated with APC alone had shorter median times to first dysphagia recurrence compared with those who also received brachytherapy or PDT (35 versus 88 and 59 days, respectively). There were no differences in overall survival.</p><p class="headingAnchor" id="H82628130"><span class="h1">CRYOSPRAY ABLATION</span><span class="headingEndMark"> — </span>Cryospray ablation (cryotherapy) is a noncontact method that uses supercooling (temperatures with nitrogen reaching -196°C) to cause cryonecrosis and has been used to palliate esophageal cancer [<a href="#rid21">21-24</a>]. Cryotherapy involves freezing and thawing cycles. The degree of tissue injury induced by cryotherapy varies depending on the rate and duration of cooling, the number of freeze-thaw cycles, and the distance from the target tissue to the origin of the spray.</p><p>In a series of 49 patients with inoperable esophageal cancer, endoscopic cryotherapy using liquid nitrogen spray was associated with improvement in dysphagia. [<a href="#rid23">23</a>]. Major adverse events included benign stricture requiring dilation (one patient) and dilation-related perforation that occurred prior to a cryotherapy session (one patient). The mean number of treatments per patient was 2.4 (range, one to six) and most patients (82 percent) received one to three cryotherapy treatments. In another series of 79 patients with esophageal cancer, a complete intraluminal response was seen in 31 of 49 patients (63 percent) who completed liquid nitrogen spray cryotherapy (30 patients were still receiving cryotherapy at the time of data collection). Benign strictures developed in 10 patients (13 percent), all of whom had undergone previous tumor therapy [<a href="#rid22">22</a>]. The median number of treatments per patient was three (range, 1 to 25). </p><p class="headingAnchor" id="H1280847347"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/120117.html" rel="external">"Society guideline links: Esophageal cancer"</a>.)</p><p class="headingAnchor" id="H26560483"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/16832.html" rel="external">"Patient education: Esophageal cancer (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H107180499"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for endoscopic palliation</strong> – Endoscopic interventions may be appropriate for palliation of dysphagia in patients with esophageal cancer in the following settings (see  <a class="medical medical_review" href="/z/d/html/2472.html" rel="external">"Management of locally advanced, unresectable and inoperable esophageal cancer"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients for whom definitive management with radiation or chemoradiotherapy is planned, but who have severe dysphagia at presentation, requiring intervention prior to therapy</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Failure to achieve adequate palliation of dysphagia with initial therapy</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recurrent dysphagia due to locoregional failure</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recurrent dysphagia due to benign strictures in patients who are successfully treated with radiation</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients are poor candidates for either chemotherapy or radiation therapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endoscopic interventions for malignant dysphagia</strong> – There are several endoscopic approaches to providing palliation from malignant dysphagia:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Placement of an esophageal stent (see <a class="local">'Endoscopic stenting'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Esophageal dilation (see <a class="local">'Esophageal dilation'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Photodynamic therapy (see <a class="local">'Photodynamic therapy'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Argon plasma coagulation (APC) (see <a class="local">'Argon plasma coagulation'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Cryospray ablation (see <a class="local">'Cryospray ablation'</a> above)</p><p></p><p class="bulletIndent1">Stenting is preferable therapy for patients with a malignant stricture and/or fistula. (See  <a class="medical medical_review" href="/z/d/html/2677.html" rel="external">"Endoscopic stenting for palliation of malignant esophageal obstruction"</a>.)</p><p></p><p class="bulletIndent1">In the absence of a fistula, optimal therapy remains controversial. The choice of endoscopic palliative method should be based upon anatomical features, patient preferences, and available expertise.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Jacobson BC, Hirota W, Baron TH, et al. The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointest Endosc 2003; 57:817.</a></li><li><a class="nounderline abstract_t">ASGE Standards of Practice Committee, Evans JA, Early DS, et al. The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointest Endosc 2013; 77:328.</a></li><li><a class="nounderline abstract_t">Shenfine J, McNamee P, Steen N, et al. A randomized controlled clinical trial of palliative therapies for patients with inoperable esophageal cancer. Am J Gastroenterol 2009; 104:1674.</a></li><li><a class="nounderline abstract_t">Siersema PD, Schrauwen SL, van Blankenstein M, et al. Self-expanding metal stents for complicated and recurrent esophagogastric cancer. Gastrointest Endosc 2001; 54:579.</a></li><li><a class="nounderline abstract_t">Boyce HW Jr. Palliation of Dysphagia of Esophageal Cancer by Endoscopic Lumen Restoration Techniques. Cancer Control 1999; 6:73.</a></li><li><a class="nounderline abstract_t">Heit HA, Johnson LF, Siegel SR, Boyce HW Jr. Palliative dilation for dysphagia in esophageal carcinoma. Ann Intern Med 1978; 89:629.</a></li><li><a class="nounderline abstract_t">Cassidy DE, Nord HJ, Boyce HW. Management of malignant esophageal strictures: Role of esophageal dilation and peroral prosthesis. Am J Gastroenterol 1981; 75:173.</a></li><li><a class="nounderline abstract_t">Lundell L, Leth R, Lind T, et al. Palliative endoscopic dilatation in carcinoma of the esophagus and esophagogastric junction. Acta Chir Scand 1989; 155:179.</a></li><li><a class="nounderline abstract_t">Hernandez LV, Jacobson JW, Harris MS. Comparison among the perforation rates of Maloney, balloon, and savary dilation of esophageal strictures. Gastrointest Endosc 2000; 51:460.</a></li><li><a class="nounderline abstract_t">Marcon NE. Photodynamic therapy and cancer of the esophagus. Semin Oncol 1994; 21:20.</a></li><li><a class="nounderline abstract_t">McCaughan JS Jr, Ellison EC, Guy JT, et al. Photodynamic therapy for esophageal malignancy: a prospective twelve-year study. Ann Thorac Surg 1996; 62:1005.</a></li><li><a class="nounderline abstract_t">Yano T, Kasai H, Horimatsu T, et al. A multicenter phase II study of salvage photodynamic therapy using talaporfin sodium (ME2906) and a diode laser (PNL6405EPG) for local failure after chemoradiotherapy or radiotherapy for esophageal cancer. Oncotarget 2017; 8:22135.</a></li><li><a class="nounderline abstract_t">Minamide T, Yoda Y, Hori K, et al. Advantages of salvage photodynamic therapy using talaporfin sodium for local failure after chemoradiotherapy or radiotherapy for esophageal cancer. Surg Endosc 2020; 34:899.</a></li><li><a class="nounderline abstract_t">Wu H, Minamide T, Yano T. Role of photodynamic therapy in the treatment of esophageal cancer. Dig Endosc 2019; 31:508.</a></li><li><a class="nounderline abstract_t">Lightdale CJ, Heier SK, Marcon NE, et al. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest Endosc 1995; 42:507.</a></li><li><a class="nounderline abstract_t">Sibille A, Lambert R, Souquet JC, et al. Long-term survival after photodynamic therapy for esophageal cancer. Gastroenterology 1995; 108:337.</a></li><li><a class="nounderline abstract_t">Corti L, Skarlatos J, Boso C, et al. Outcome of patients receiving photodynamic therapy for early esophageal cancer. Int J Radiat Oncol Biol Phys 2000; 47:419.</a></li><li><a class="nounderline abstract_t">Eickhoff A, Jakobs R, Schilling D, et al. Prospective nonrandomized comparison of two modes of argon beamer (APC) tumor desobstruction: effectiveness of the new pulsed APC versus forced APC. Endoscopy 2007; 39:637.</a></li><li><a class="nounderline abstract_t">Sigounas DE, Krystallis C, Couper G, et al. Argon plasma coagulation compared with stent placement in the palliative treatment of inoperable oesophageal cancer. United European Gastroenterol J 2017; 5:21.</a></li><li><a class="nounderline abstract_t">Rupinski M, Zagorowicz E, Regula J, et al. Randomized comparison of three palliative regimens including brachytherapy, photodynamic therapy, and APC in patients with malignant dysphagia (CONSORT 1a) (Revised II). Am J Gastroenterol 2011; 106:1612.</a></li><li><a class="nounderline abstract_t">Cash BD, Johnston LR, Johnston MH. Cryospray ablation (CSA) in the palliative treatment of squamous cell carcinoma of the esophagus. World J Surg Oncol 2007; 5:34.</a></li><li><a class="nounderline abstract_t">Greenwald BD, Dumot JA, Abrams JA, et al. Endoscopic spray cryotherapy for esophageal cancer: safety and efficacy. Gastrointest Endosc 2010; 71:686.</a></li><li><a class="nounderline abstract_t">Kachaamy T, Prakash R, Kundranda M, et al. Liquid nitrogen spray cryotherapy for dysphagia palliation in patients with inoperable esophageal cancer. Gastrointest Endosc 2018; 88:447.</a></li><li><a class="nounderline abstract_t">Kachaamy T, Sharma N, Shah T, et al. A prospective multicenter study to evaluate the impact of cryotherapy on dysphagia and quality of life in patients with inoperable esophageal cancer. Endoscopy 2023; 55:889.</a></li></ol></div><div id="topicVersionRevision">Topic 2273 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12776026" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The role of endoscopy in the assessment and treatment of esophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23410694" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The role of endoscopy in the assessment and treatment of esophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19436289" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A randomized controlled clinical trial of palliative therapies for patients with inoperable esophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11677473" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Self-expanding metal stents for complicated and recurrent esophagogastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10758537" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Palliation of Dysphagia of Esophageal Cancer by Endoscopic Lumen Restoration Techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/82417" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Palliative dilation for dysphagia in esophageal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Management of malignant esophageal strictures: Role of esophageal dilation and peroral prosthesis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2472723" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Palliative endoscopic dilatation in carcinoma of the esophagus and esophagogastric junction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10744819" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Comparison among the perforation rates of Maloney, balloon, and savary dilation of esophageal strictures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7992103" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Photodynamic therapy and cancer of the esophagus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8823080" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Photodynamic therapy for esophageal malignancy: a prospective twelve-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28212527" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A multicenter phase II study of salvage photodynamic therapy using talaporfin sodium (ME2906) and a diode laser (PNL6405EPG) for local failure after chemoradiotherapy or radiotherapy for esophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31139985" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Advantages of salvage photodynamic therapy using talaporfin sodium for local failure after chemoradiotherapy or radiotherapy for esophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30667112" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Role of photodynamic therapy in the treatment of esophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8674919" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7835574" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Long-term survival after photodynamic therapy for esophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10802369" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Outcome of patients receiving photodynamic therapy for early esophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17611919" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prospective nonrandomized comparison of two modes of argon beamer (APC) tumor desobstruction: effectiveness of the new pulsed APC versus forced APC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28405318" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Argon plasma coagulation compared with stent placement in the palliative treatment of inoperable oesophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670770" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Randomized comparison of three palliative regimens including brachytherapy, photodynamic therapy, and APC in patients with malignant dysphagia (CONSORT 1a) (Revised II).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17367523" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cryospray ablation (CSA) in the palliative treatment of squamous cell carcinoma of the esophagus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20363410" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Endoscopic spray cryotherapy for esophageal cancer: safety and efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29750984" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Liquid nitrogen spray cryotherapy for dysphagia palliation in patients with inoperable esophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37268010" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A prospective multicenter study to evaluate the impact of cryotherapy on dysphagia and quality of life in patients with inoperable esophageal cancer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
